LONA

LeonaBio, Inc.

Nasdaq· Biological Products, (No Diagnostic Substances)· CIK 0001620463 Biotech & Drug Discovery

$4.76 −0.08 (−1.65%)

Oct 26 4:00 PM ET · prev $4.84

Market cap

$46.8M

Nano cap

Consensus

Buy

90% Buy or better · 10 analysts

Median target

$17.00

+257% · range $15.00–20.00

Next earnings

Nov 5

in 9 days · EPS est. −$0.69

1 year

+14.7%

from $4.15 · Oct 27

30 days

+65.9%

from $2.87

52-week range

$2.87–11.68

−59% from high · low Sep 28

Avg volume 20D

442.1K

Oct 1 spike 6.30M

Short interest

🔒 Subscribers only

Insider net

−$49.1K

0 buyers · 4 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 1 report · 90 days

Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score

Avg score

·Next Earnings date, Nov 5, 2026

Strongest🔒 Fresh report (last 24h), subscribers only

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

S Mar 4 4 insiders sell $49.1K at $5.37
R Mar 26 LeonaBio (LONA) reported its 2025 financial results and provided upd…
E Apr 23 FDA: LeonaBio to Host Virtual Key Opinion Leader Event Highligh…
R Apr 23 LeonaBio announced a virtual Key Opinion Leader event featuring two…
A Jul 30 Citizens upgrades
X Sep 15 Short interest falls 41.3% to 23.7K
E Oct 1 Trading halt: Halt Resumed: LONA — trading resumed after LUDP (Volatilit…
E Oct 1 Trading halt: Trading Halt: LONA — LUDP (Volatility Trading Pause)

Signal stack

Where each data set points today.

InsidersBEARISH

4 insiders sold $49.1K.
InstitutionsMIXED

Q2 2026: 3 added (0 new), 4 trimmed or exited.
AnalystsBULLISH

9 of 10 rate it Buy or better. Every target is above the price.
EstimatesRISING

Current-quarter EPS estimate −$0.710 → −$0.685 over 90 days. 2 up, 1 down in 30 days.
TrendDOWNTREND

24% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
VANGUARD CAPITAL MANAGEMENT LLC	ADD	275,233	$2.5M
BlackRock, Inc.	ADD	79,186	$727.7K
OSAIC HOLDINGS, INC.	TRIM	4,580	$42.1K
JPMORGAN CHASE & CO	DOUBLED	2,012	$17.8K
ROYAL BANK OF CANADA	TRIM	844	$8.0K
UBS Group AG	NEAR_EXIT	196	$1.8K
MORGAN STANLEY	NEAR_EXIT	89	$818.00
GEODE CAPITAL MANAGEMENT, LLC	DOUBLED	80,323	$826.2K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts

Buy 90% rate it Buy or better

Strong Buy2Buy7Hold1Sell0Strong Sell0

12-month targets · 3 analysts

$4.76 $15.00 $17.00 $20.00

Price is below the lowest target. Median implies +257%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 19, 2026	Mizuho MAINTAIN	MAINTAIN	Outperform
Aug 17, 2026	Citizens MAINTAIN	MAINTAIN	Market Outperform
Jul 30, 2026	Citizens UPGRADE	UPGRADE	Market Outperform
May 27, 2026	Piper Sandler INITIATE	INITIATE	Overweight

Insider ledger

Form 4

bought · 0 insiders

$49.1K

sold · 4 insiders

Date	Insider	Type	Value
Oct 26, 2026	🔒 Fresh data, subscribers only	EXERCISE
Jun 23, 2026	PERCEPTIVE ADVISORS LLC Director	AWARD	28,000 sh
Jun 23, 2026	PICKERING GRANT Director	AWARD	28,000 sh
Jun 23, 2026	Kosacz Barbara Director	AWARD	28,000 sh
Jun 23, 2026	JOHNSON JAMES A Director	AWARD	28,000 sh
Jun 23, 2026	EDELMAN JOSEPH Director	AWARD	28,000 sh
Jun 23, 2026	Romano Kelly A Director	AWARD	28,000 sh
Jun 23, 2026	Panzara Michael A. Director	AWARD	28,000 sh

Earnings setup

Estimates

Nov 5

reports in 9 days

−$0.69

EPS estimate, this quarter

+4%

estimate change, 90 days

2↑ 1↓

revisions, 30 days

Current-quarter EPS estimate

−$0.710

90d

−$0.710

60d

−$0.685

30d

−$0.685

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.69	-$0.84–-$0.53	+0.0%	$0.00
Next Q	-$0.60	-$0.88–-$0.24	+0.0%	$0.00
Current FY	-$2.83	-$4.11–-$1.96	+0.0%	$0.00
Next FY	-$2.34	-$4.06–-$1.15	+0.0%	$0.00